---
figid: PMC4621888__oncotarget-06-18250-g001
figtitle: 'Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder'
organisms:
- NA
pmcid: PMC4621888
filename: oncotarget-06-18250-g001.jpg
figlink: /pmc/articles/PMC4621888/figure/F1/
number: F1
caption: PI3K mediated activation of RAS-MAPK-JNK pathway, AKT-ERK and ATK-mTORC2
  pathway leads to survival of neoplastic MCs. Recent studies highlight newer pathways
  mediated by SHP2, FAK, ROCK are described with corresponding inhibitors that hold
  promise. (1) SHP2 and P13K/GAB2 induced AKT/ERK activation can be inhibited using
  SHP2 specific inhibitor IIBO8, (2) FAK/TIAM1/RAC1/PAK1 mediated nuclear translocation
  of active STAT5 in SM patients can be inhibited by targeting FAK and PAK1 (4) with
  inhibitors, (3) PI3K mediated activation of RAC1 via VAV1 can be targeted using
  novel RAC1 inhibitor Ehop-016, (5) PI3K/RHOA mediated activation of ROCK1 can be
  targeted by inhibitor H-1152 against ROCK1, (6) targeting PI3K using inhibitors
  that have shown promise in other malignancies [], (7) targeting AKT (GSK2141795),
  (8) inhibiting JAK with Roxolitinib, Lestaurtinib, Pacritinib, and (9) targeting
  epigenetic regulators ASXL1, DNMT3A and TET2 by 5-azacytidine (5′-AZA) and 5-aza-2′
  deoxycytidine (Decitabine/DAC).
papertitle: 'Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder.'
reftext: Anindya Chatterjee, et al. Oncotarget. 2015 Jul 30;6(21):18250-18264.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9164125
figid_alias: PMC4621888__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC4621888__F1
ndex: a63732ba-df0f-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4621888__oncotarget-06-18250-g001.html
  '@type': Dataset
  description: PI3K mediated activation of RAS-MAPK-JNK pathway, AKT-ERK and ATK-mTORC2
    pathway leads to survival of neoplastic MCs. Recent studies highlight newer pathways
    mediated by SHP2, FAK, ROCK are described with corresponding inhibitors that hold
    promise. (1) SHP2 and P13K/GAB2 induced AKT/ERK activation can be inhibited using
    SHP2 specific inhibitor IIBO8, (2) FAK/TIAM1/RAC1/PAK1 mediated nuclear translocation
    of active STAT5 in SM patients can be inhibited by targeting FAK and PAK1 (4)
    with inhibitors, (3) PI3K mediated activation of RAC1 via VAV1 can be targeted
    using novel RAC1 inhibitor Ehop-016, (5) PI3K/RHOA mediated activation of ROCK1
    can be targeted by inhibitor H-1152 against ROCK1, (6) targeting PI3K using inhibitors
    that have shown promise in other malignancies [], (7) targeting AKT (GSK2141795),
    (8) inhibiting JAK with Roxolitinib, Lestaurtinib, Pacritinib, and (9) targeting
    epigenetic regulators ASXL1, DNMT3A and TET2 by 5-azacytidine (5′-AZA) and 5-aza-2′
    deoxycytidine (Decitabine/DAC).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - KIT
  - PTPN11
  - GAB2
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - PTK2
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - RAC1
  - RNASE1
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - RHOA
  - EPHB2
  - PAK1
  - PKN1
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - ROCK1
  - STAT5A
  - STAT5B
  - STAT1
  - SMCP
  - MOCOS
  - ZC4H2
  - STAT3
  - ASXL1
  - DNMT3A
  - TET2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - SPP1
  - GSK2141795
  - H-1152
  - Cancer
  - Noonan syndrome
---
